
TUESDAY 22 OCTOBER	
12:00-14:00 · Registration Foyer REGISTRATION	
14:00-16:30 · Plenary Hall · PLENARY SESSION 1: ESGCT 2024 Opening: Gene Therapy for Genetic Diseases	n
Chairs: Juan Bueren, CIEMAT/CIBERER/IIS. F. Jiménez Díaz, Madrid; Alberto Auricchio, Tigem, Naples; Luigi Naldini, SR-Tiget, Milan	·· 🖕
Juan Bueren, CIEMAT/CIBERER/IIS. F. Jiménez Díaz, Madrid; Alberto Auricchio, Tigem, Naples; Luigi Naldini, SR-Tiget, Milan Welcome	
Alberto Auricchio, Tigem, Naples INV01: ExpEditing AAV gene therapy	
Yilai Shu, Fudan University, Shanghai INV02: AAV1-hOTOF Gene Therapy for Autosomal Recessive Deafness 9	
Franco Locatelli, IRCCS, Ospedale Pediatrico Bambino Gesù Rome, Catholic University of the Sacred Heart, Rome INV03: Haemoglobinopathies gene therapy	
Amit Khera, Verve Therapeutics, Cambridge, MA INV04: Developing single-course gene editing medicines to treat cardiovascular disease	
16:30-17:00 · Forum and Registration Foyer COFFEE BREAK	
17:00-19:30 · Plenary Hall · PARALLEL SESSION 2a: The challenges of preclinical development – how host factors and species-specific differences impact translation	N
Chairs: Hildegard Büning, Hannover Medical School; Stylianos Michalakis, LMU, Munich	-
Luk Vandenberghe, Harvard Medical School INV05: Bridging the species gap in AAV development	
Juliette Hordeaux, University of Pennsylvania INV06: Safety profile of recombinant AAV vectors in nonhuman and human primates: bench to bedside and back	
Marina Stavrou, The Cyprus Institute of Neurology and Genetics, Nicosia OR001: Dose escalation studies in mice and NHPs confirm biodistribution, target engagement and safety of AAV9-miR871 and support its translation the treatment of CMT1A neuropathy	for
Linus Wiora, German Center for Neurodegenerative Diseases (DZNE), Tübingen OR002: Developing a screening platform for AAV tropism in iPSC-derived neural cells	
Sumitava Dastidar, University College London OR003: A human, multi-lineage and multi-organoid platform to assess tropism, toxicity and efficacy of neuromuscular gene therapy vectors	
Florencia Haase, Children's Medical Research Institute, Westmead OR004: Understanding the involvement of AAVR in AAV entry and transduction of the central nervous system	
Randy Chandler, National Institue of Health, Washington OR005: The genomic architecture of 24 carcinogenic recombinant-AAV integrations in mice: Implications for human gene therapy safety	
Pedram Moeini Gavgani, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona OR006: Transcriptional findings of unfolded protein response/integrated stress response in the liver of non-human primates subjected to high doses of recombinant AAV vector	f





WEDNESDAY 23 OCTOBER		
	08:00-08:30 · Registration Foyer REGISTRATION	
	08:30-10:30 · Plenary Hall · PARALLEL SESSION 3a: AAV vectors as tools in gene therapy of rare diseases – recent development to improve efficacy and safety Chairs: Juliette Hordeaux, University of Pennsylvania, Fatima Bosch, UAB, Barcelona	
	Gloria Gonzalez-Aseguinolaza; <i>CIMA, University of Navarra, Pamplona</i> INV13: Gene therapy for liver diseases — progress and challenges	
	Ian Alexander, University of Sydney INV14: AAV vectors and the paediatric liver as a therapeutic target	
	Guo-jie Ye, Exegenesis Bio OR025: Efficient Retinal Transduction and Excellent Inhibitory Effect on Retinal Detachment of EXG202 delivered by intravitreal injection in NHP and a Severe Neovascularization and vascular leakage Mouse Model	
	Shanzhong Zhang, Otovia Therapeutics OR026: OTOV101 Gene therapy for autosomal recessive deafness 9: a multicenter, open-label, single-arm, investigator initiated intervention study	
	Serge Braun, Genethon, Evry OR027: GNT0004, Genethon's AAV8 vector-delivered microdystrophin gene therapy for Duchenne muscular dystrophy: first data from Phase 1/2 part of GNT-016-MDYF all-in-one clinical trial in ambulant boys	
	Francesca Ferrante, Spur Therapeutics OR028: Results from GALILEO-1, a first-in-human clinical trial of FLT201 gene therapy in patients with Gaucher disease Type 1	
	08:30-10:30 · Meeting Room 1 · PARALLEL SESSION 3b: Oncolytic Therapy and Cancer Gene Therapy In collaboration with the JSGCT	
	Chairs: Vincenzo Cerullo, University of Helsinki, Masahiro Toda, Keio University School of Medicine, Tokyo	
	Elisa Scarselli, Nouscom, Rome INV15: Genetic vaccines journey: from cancer treatment to interception	
	Masahiro Toda, Keio University School of Medicine, Tokyo INV16: Gene therapy for brain tumors using neural stem cells derived from genome-edited iPS cells	
	Claudia Pinacchio, Bambino Gesù Children's Hospital, Rome OR029: Enhanced Immunotherapy for High-Grade Gliomas Using Oncolytic Virus Armed with Co-Stimulatory Molecule and EphA2-Engager	
	Fritiof Åkerström, Asgard Therapeutics AB, Medicon Village, Lund OR030: A cancer immunotherapy modality based on dendritic cell reprogramming <i>in vivo</i>	
	Giovanna Giacca, SR-Tiget, Milan OR031: An hemato-chimeric mouse model hosting human liver-resident macrophages for translational studies using in vivo lentiviral-based gene therapies	
	Jella van de Laak, Faculty of Health, Medicine & Life Sciences (FHML), Maastricht University OR032: Genetically modified bacteria as anti-cancer Trojan horse; intratumoural delivery of immunotherapy by Clostridium sporogenes	
	08:30-10:30 · Meeting Room 2 · PARALLEL SESSION 3c: Infectious Diseases / Vaccines	
	Chairs: Karine Breckpot, VUB, Brussels; Chantal Pichon, Centre de Biophysique Moléculaire, CNRS, Orléans Patrick Arbuthnot, University of Witwatersrand INV17: Formulation of mRNA sequences in bio-renewable lipid nanoparticles to counter infection with Mycobacterium tuberculosis and other pathogens	
	Asaf Poran, BioNTech INV18: A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease	
	Kristie Bloom, University of the Witwatersrand OR033: Mycobacterium Tuberculosis polyprotein mRNA vaccines designed to augment protein sorting enhance immunogenicity and protection in preclinical studies	
	Anja Ehrhardt, Witten/Herdecke University OR034: Novel adenovirus vaccine vectors lacking binding to the thrombosis associated Platelet Factor 4 protein	
	Norbert Pardi, University of Pennsylvania OR035: Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications	
	Angelo Raggioli, Reithera Srl OR036: GRAd as vaccine platform for COVID-19, HIV, and global health	

WEDNESDAY 23 OCTOBER
08:30-10:30 · Auditorium · PARALLEL
SESSION 3d: Metabolic Diseases: Preclinical
Chairs: Yoshikatsu Eto, Tokyo Jikei University; Nicola Brunetti-Pierri, TIGEM, Naples
Dwight Koeberl, Duke University, Durham, NC INV19: Gene Editing for Glycogen Storage Disease
Brian Bigger, The University of Edinburgh INV20: Stem cell gene therapy for Childhood Dementias – a Sanfilippo story
Louisa Jauze, Genethon, Evry OR037: Liver-directed AAV gene transfer corrects hypoglycemia and metabolic impairment in a GSDIII mouse model in the long term.
Federica Esposito, Tigem, Naples OR038: Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases
Stefania Crippa, SR-Tiget, Milan OR039: Pre-clinical development of an ex-vivo lentiviral-based Hematopoietic Stem/Progenitor Cells-Gene Therapy (HSPC-GT) for Mucopolysaccharidosis type IVA (MPSIVA) as part of an innovative GT platform approach for LSDs with skeletal involvement.type II
Fabio Catalano, Erasmus MC University Medical Center, Rotterdam OR040: Domain-substituted IGF2 tag to modulate receptor targeting during lentiviral gene therapy for Mucopolysaccharidosis type II
10:30-11:00 · Forum and Registration Foyer COFFEE BREAK
11:00-13:00 · Plenary Hall · PLENARY
SESSION 4: Cancer Gene Therapy Chairs: Chiara Bonini, San Raffaele Scientific Institute, Milan, Waseem Qasim, UCL London
Waseem Qasim, University College London INV21: Genome-editing & developments for CAR T cells
Concetta Quintarelli, Bambino Gesù Children's Hospital, IRCCS, Rome INV22: CAR T Cells for Treating Pediatric Cancers: Challenges and Opportunities
Bernhard Gentner, Ludwig Institute for Cancer Research, Lausanne INV23: Genetic reprogramming of tumor-associated myeloid cells to awaken anti-cancer immunity
Marta Alonso, University of Navarra, Pamplona INV24: Overcoming oncolytic virus resistance to improve the treatment of pediatric brain tumors
13:00-14:00 · Forum and Registration Foyer LUNCH
13:30-15:00 · Concourse Level -1 and Mezzanine Concourse POSTER SESSION II (Even numbers up to P0520)
13:30-14:30 · Meeting Room 1 LUNCHTIME SYMPOSIUM: PlasmidFactory - A spotlight on plasmid and minicircle DNA starting materials for AAV vectors
Chairs: Eduard Ayuso, DINAMIQS; Dr. Marco Schmeer, PlasmidFactory GmbH
Hildegard Büning, Hannover Medical School (MHH) Improving the quality of AAV vector preparations by exchanging plasmids by minicircles
Michela Gentile, ReiThera srl Optimization of the two-plasmid system for AAV production
Kristian Müller, Bielefeld University A hitchhiker's guide to ITR stability
Ram Shankar, PlasmidFactory GmbH ITR maintenance and in-depth analysis for AAV transfer plasmids
13:30-14:30 · Auditorium LUNCHTIME SYMPOSIUM: Sartorius - Setting the Standard in Differentiated Development: Innovative Approaches to Scalable PSC Production
Chair: Lorraine Borland, Sartorius
Lorraine Borland, Sartorius Introduction
Victor Buñuel Sorribas, Novo Nordisk Scalable Manufacturing of Pluripotent Stem Cell Therapies: Revolutionizing Cell Harvesting with Ksep Systems
Robert Zweigerdt, Hannover Medical School Advanced manufacturing of hPSC-cardiomyocytes and preclinical transplantation for heart repair
Mark A. Skylar-Scott, Betty Irene Moore Children's Heart Center Liter Scale Production of iPSC-Derived Cardiomyocytes

	WEDNESDAY 23 OCTOBER
	13:30-14:15 · Satellite Room - M1 LUNCHTIME WORKSHOP: How to get published
	Kevin Davies, Mary Ann Liebert Thomas Gallagher, University of Massachusetts
	Kevin Davies, the founding editor of <i>Nature Genetics</i> and Executive Editor of <i>The CRISPR Journal</i> , and Thomas Gallagher, the Managing Editor of <i>Human Gene Therapy</i> , will discuss the publishing process to provide insights from the perspective of a journal and publishing company to help scientists navigate the manuscript submission, peer review, and publication process. <u>More information ></u>
,	Attendees must sign up in advance. Register at https://forms.office.com/e/YnrRv0EM3Y
:	15:00-17:00 · Plenary Hall · PLENARY SESSION 5: Advanced Technologies for the Treatment of Human Diseases Chairs: Toni Cathomen, University of Freiburg, Matthew Porteus, Stanford University
	Angelo Lombardo, SR-Tiget, Milan INV25: Programming permanent gene repression by epigenetic editing
	Zoya Ignatova , <i>University of Hamburg</i> INV26: Unlocking the unreachable: harnessing tRNA therapeutics for rare genetic conditions
	Paula Rio, Ciemat/CIBERER/IIS-Fundación Jiménez Díaz, Madrid INV27: Hematopoietic stem cell gene therapy: Overcoming challenges in Fanconi anemia
	Samuel Sternberg, Columbia University, New York, NY INV28: Discovery and development of CRISPR-associated transposases for RNA-guided gene insertion
	17:00-17:30 · Forum and Registration Foyer COFFEE BREAK
:	17:30-19:30 · Plenary Hall · PARALLEL SESSION 6a: Beyond conventional: next generation vectors in gene and cell therapy: Part 1 (Capsid) Chairs: Luk VandenBerghe, Harvard Medical School; Gloria Gonzalez Aseguinolaza, CIMA, University of Navarra, Pamplona
	Hildegard Büning, Hannover Medical School INV29: Capsid engineering to empower the adeno-associated virus (AAV) vector system for its new "fields of action"
	Fabian John, Paul-Ehrlich-Institut, Langen OR041: Selective transduction of lymphoid cell subsets with bispecific DART-AAVs
	Angela Enrica Araujo, Hannover Medical School OR042: Development of engineered AAV variants to target T lymphocytes in vivo
	Alaa Siam, University College London OR043: Investigating the safety, efficacy and dynamics of lentiviral and AAV gene therapies in a mouse model of maple syrup urine disease
	Qizhao Wang, <i>AAVnerGene Inc</i> OR044: AAV(BBB)s: Novel AAV Variants with 500-fold Higher BBB Crossing Efficiency in NHP
	Andrea Pérez Iturralde, The University of Sydney, Westmead OR045: Towards the translation of an AAV-mediated gene therapy for an incurable disease
	Yumi Sano, Heidelberg University OR046: Critical role of VP3 N-terminal residues and variable capsid regions for bocaparvovirus transduction
:	17:30-19:30 · Meeting Room 1 · PARALLEL SESSION 6b: Skin, Pulmonary and Skeletal Diseases Chairs: Alain Hovnanian, Institut Imagine, Paris; Uta Griesenbach, Imperial College, London
	Marta Garcia Diez, CIEMAT/CIBERER, Madrid INV30: Personalized preclinical gene editing protocols for ex vivo and in vivo correction of rare skin disease
	Sarah Hedtrich, Charité, Berlin INV31: In situ gene editing as a topically applicable treatment option for genodermatoses
	Uta Griesenbach, Imperial College, London INV32: Gene Therapy for Rare Lung Diseases
	Alex Bassons Bascuñana, Ciemat, Madrid OR047: Efficient base and prime editing to correct COL7A1 patogenic variants in primary RDEB patient keratinocytes
	Simone Ponta, ETH Zurich OR048: Biofabrication of a hyaline cartilage graft mimicking native architecture from genetically engineered MSCs with enhanced chondrogenic potential

	WEDNESDAY 23 OCTOBE	R
17:30-19:30 · Meeting Room 2 · I SESSION 6c: Non Viral Vector		biotechne
Chairs: Zoltan Ivics, Fraunhofer Insti	ute for Cell Therapy and Immunology, Leipzig; Ray Schiffelers, Un	
Frank Buchholz, Technical Univer INV33: Engineering Designer-Rec	rsity Dresden ombinases for therapeutic genome editing	
Ross Wilson, University of Berke INV34: Highly efficient in vivo edi	ey ing of neurons via peptide-mediated delivery of CRISPR en:	zymes
Russell Monds, Generation Bio, OR049: iqDNA is an engineered	Cambridge MA NA cargo that avoids innate immune activation while retain	ing durable transgene expression
Jacek Lubelski, NanoCell Thera, OR050: tLNPs can effectively del	vertics ver DNA to T-cells and generate long-acting CAR-T cells in	vivo.
Guillaume Mondon, Paris Cité U OR051: Exon skipping using palr epidermolysis bullosa.	niversity itoyl conjugated tricyclo-DNA antisense oligonucleotides re	stores protein expression in vivo in recessive dystrophic
Thomas Hansen, Circio OR052: Optimization of in vitro a	d in vivo performance of circVec, a vector-based circular R	NA expression platform for enhanced gene therapy
17:30-19:30 · Auditorium · PARA SESSION 6d: Hematopoietic		
Chairs: Claire Booth, University Coll	ge London; Jose Carlos Segovia Sanz, Ciemat/Ciberer, Madrid	
Amit Nathwani, University Colleg INV35: Gene Therapy for Hemop	e London illia: From bench side to Market Authorization	
Don Kohn, UCLA INV36: Hematopoietic Stem Cell	Gene Therapy	
Emmanuelle Six, Imagine Institu OR053: Second occurrence of LI	e Paris IO2-associated clonal T cell proliferation 20 years after garr	ma-retrovirus-mediated gene therapy for SCIDX1
Martina Fiumara, SR-Tiget, Mila OR054: Modeling of VEXAS sync dominance during aging	rome by Base Editing uncovers poisoning of healthy hemato	ppoiesis as an unanticipated mechanism driving clonal
Michela Milani, SR-Tiget, Milan OR055: In vivo gene transfer into	haematopoietic stem and progenitor cells for the treatment	of Fanconi Anemia
Frank Staal, Leiden University M OR056: Gene therapy for Recom	dical Center	

THURSDAY 24 OCTOBER

monsbar 24 GOTOBEN
08:30-09:00 · Registration Foyer REGISTRATION
09:00-11:00 · Plenary Hall · PARALLEL SESSION 7a: Improving Gene Editing Outcome
Chairs: Paula Rio, Ciemat/Ciberer, Madrid; Julian Grünewald, TUM Munich
Raffaella Di Micco, SR-Tiget, Milan INV37: Mechanistic insights to advance HSC-based gene editing applications
Matthew Porteus, Stanford University INV38: Improving Homology Directed Repair Genome Editing
Lei Lei, University of Freiburg OR057: Cell-Type and Time-Resolved Genotoxicity of Base Editing
Daniele Canarutto, SR-Tiget, Milan OR058: Efficient long range gene editing and enrichment of lymphocytes and hematopoietic stem and progenitor cells with the desired editing outcome
Giandomenico Turchiano, University College London OR059: Chromosomal aberrations, NHEJ scarless repair, recurrent nuclease cleavage and DSB half-life; all at once.
Deborah Cipria, SR-Tiget, Milan OR060: Towards safer engineering of T cells for cancer immunotherapy by polyfunctional editing
09:00-11:00 · Meeting Room 1 · PARALLEL SESSION 7b: Hematopoietic, PID and Bleeding II
Chairs: Amit Nathwani, UCL London, Don Kohn, UCLA
Denise Sabatino, University of Pennsylvania, Philadelphia, PA INV39: Innovations in factor VIII biology for next generation hemophilia A gene therapy
Rosa Bacchetta, Stanford University School of Medicine, CA INV40: IPEX gene therapy trial with the engineered Treg-like cells
Cesare Canepari, SR-Tiget, Milan OR061: Enhancing the potency of in vivo lentiviral gene therapy to hepatocytes for hemophilia
Ivan Krivega, SonoThera OR062: Development of a non-viral genetic medicine for Hemophilia A by targeted transcutaneous ultrasound-mediated gene delivery
Wolfgang Miesbach, Goethe University Hospital, Frankfurt am Main OR063: Stable factor IX expression and sustained reductions in factor IX use 7 years after gene therapy with AMT-060 in adults with haemophilia B
Pervinder Sagoo, Orchard Therapeutics, London OR064: Haematopoietic stem cell gene therapy as a treatment for NOD2-deficient severe Crohn's Disease
09:00-11:00 · Meeting Room 2 · PARALLEL SESSION 7c: Cardio and Muscular
Chairs: Mauro Giacca, King's College London; Eduard Ayuso, DINAMIQS
Matthew Wood, Oxford University INV41: Accelerating genome based therapies for rare neuromuscular diseases
Dan Peer, University of Tel Aviv INV42: Cell Specific Delivery of RNAs Using Targeted Lipid Nanoparticles: from Vaccines to Therapeutic Genome Editing.
Mateusz Tomczyk, King's College London OR065: mRNA therapy for acute myocardial infarction
Edith Renaud, Genethon Evry OR066: Ten-year efficacy of gene therapy in a canine model of X-linked myotubular myopathy
Yann Chong Tan, Nuevocor Pte. Ltd. OR067: NVC-001 – an AAV gene therapy for LMNA-related dilated cardiomyopathy
Laura Lalaguna, CNIC, Madrid OR068: AAV delivery of wild type TMEM43 as a novel therapeutic approach for arrhythmogenic right ventricular cardiomyopathy type 5

THURSDAY 24 OCTOBER
09:00-11:00 · Auditorium · PARALLEL SESSION 7d: CNS gene therapy Chairs: Nathalie Cartier, AskBio, Paris; Alberto Auricchio, Tigem Naples
Krystof Bankiewicz, AskBio INV43: Clinical Progress and Plans for Aav2GDNF Gene Therapy for Parkinson's Disease
Isabel Aznarez, Stoke Therapeutics INV44: The zorevunersen story: insights from the development of the first potential disease-modifying medicine for Dravet syndrome
Florian Eichler, Massachusetts General Hospital OR069: Results from the CANaspire Gene Therapy Trial for Canavan Disease: Safety, Biomarker, Imaging, and Clinical Outcome Data from the Completed Low-dose Cohort
Sue Browne, Passage Bio, Philadelphia PA OR070: Non-clinical and early clinical development of PBFT02, an AAV gene therapy for FTD with GRN mutations (FTD-GRN)
Dolan Sondhi, Weill Cornell Medical College OR071: Twenty-year Survival Analysis of CNS AAV2-mediated Gene Therapy for CLN2 Disease
Anne Hillen, SR-Tiget, Milan OR072: Targeting astrocytes with editing technologies to treat Alexander Disease
09:00-10:30 · Satellite Room -M1 / PARALLEL SESSION 7e: T2EVOLVE/JOIN4ATMP Roundtable Discussion: Accelerating Cell and Gene Therapy development through Extrapolation and Platform Approaches
Chairs: Carmen Sanges, University Hospital Würzburg; Delphine Ammar, Astellas (IMI T2Evolve)
Carmen Sanges, University Hospital Würzburg and Delphine Ammar, Astellas (IMI T2Evolve) Introduction
Mark Stewart, Friends of Cancer Research Extrapolation framework for accelerating next generation therapies
Macarena Roman Alonso, Vall D'Hebron Institute of Oncology (VHIO) Case Study: A parent-child platform approach for the development of CAR T cell therapies targeting solid tumors using a common retroviral vector and manufacturing process
Maria Ester Bernardo, Telethon / Join4ATMP Case Study: An innovative platform approach for the development of ex-vivo gene therapies (HSC-GT) for lysosomal storage disorders (LSD) with skeletal involvement
Roundtable Discussion Academic developer: Julio Delgado, Hospital Clinic Barcelona Industry developer: Agnes Yeboah, Bristol Myers Squibb Industry developer: William McAree, Kite Gilead EMA representatives: Illona Reischl, AGES & EMA CAT Chair & Paolo Foggi, AIFA
11:00-11:30 · Forum and Registration Foyer COFFEE BREAK
11:30-13:30 · Plenary Hall · PLENARY SESSION 8: Presidential Symposium Chairs: Juan Bueren, CIEMAT/CIBERER/IIS. F. Jiménez Díaz, Madrid; Luigi Naldini, SR-Tiget, Milan, Alberto Auricchio, Tigern, Naples
Juan Bueren, <i>Ciemat, Madrid</i> INV45: Presidential address
Douglas Higgs, University of Oxford INV46: Switching on an embryonic gene to cure an adult disease
OUTSTANDING ACHIEVEMENT AWARD Human Chiara Bonini, San Raffaele Hospital Milan Gene INV47: T-cell engineering to fight cancer and autoimmunity Therapy Hung Angle Lided, Inc. Hung Angle Lided, Inc.
CAREER PROGRESSION AWARD Manlio Fusciello, University of Helsinki OR073: Cancer Vaccines: Anti-tumoral T cell therapy on demand
CAREER PROGRESSION AWARD Serena Scala, SR-Tiget, Milan OR074: Studying human Hematopoietic Stem/Progenitor Cell trafficking: from basic biology to clinical translation
Award ceremony for early careers and travel awards

THURSDAY 24 OCTOBER	
13:30-14:30 · Forum and Registration Foyer LUNCH	
13:30-14:00 · Plenary Hall ESGCT AGM	
14:00-15:00 · Meeting Room 1 LUNCHTIME SYMPOSIUM: MaxCyte - Combining CRISPR and Transposon-based Technologies for Improved CAR-T Therapies	ıxCyte'
Juan Roberto Rodriguez-Madoz, Cima Universidad de Navarra	
14:00-15:00 · Auditorium LUNCHTIME SYMPOSIUM: ERC - Unlocking success: insights from an ERC Project Adviser and ERC Grantees to maximize your chances Chairs: Janka Mátrai, ERC, Orsolya Symmons, EIC	erc
Paola Cattaneo, University of Milan and Monzino Cardiology Center Marc Güell, Pompeu Fabra University, Barcelona	
Roundtable	
14:00-15:30 · Concourse Level -1 and Mezzanine Concourse POSTER SESSION III (Uneven numbers from P0521 to P1045)	
15:30-17:30 · Plenary Hall · PARALLEL SESSION 9a: <i>in vivo</i> Gene Editing in Preclinical Models	
Chairs: Annarita Miccio, Institut Imagine Paris, Samuele Ferrari, SR Tiget, Milan	
Gerald Schwank, University of Zurich INV48: In vivo genome editing in mice and macaques using mRNA-LNP delivery	
Cynthia Dunbar, NHLBI, NIH INV49: Impact of Gene Editing on HSPC Dynamics in Macaques	
Gabriele Casirati, Boston Children Hospital OR075: Epitope editing combined with extended schedule anti-KIT antibody treatment enhances immune-based in vivo selection of multiplex g engineered cells	jenome-
Michael Holmes, Tessera Therapeutics OR076: RNA Gene Writers drive therapeutically relevant in vivo correction of monogenic disease mutations in the liver and hematopoietic stem	cells
Jeremy Duffield, Prime Medicine OR077: LNP delivered Prime Editors restore glycemic control in humanized rodent models of Glycogen Storage Disease Type 1b (GSD1b)	
Maëlle Ralu, Genethon Evry OR078: CRISPR-Cas9 mediated endogenous utrophin upregulation improves Duchenne Muscular Dystrophy	
15:30-17:30 · Meeting Room 1 · PARALLEL SESSION 9b: Immune Responses to Gene Therapy	
Chairs: Carmen Unzu, CIMA Universidad de Navarra, Pamplona; Federico Mingozzi, Nava Therapeutics	
Anna Kajaste-Rudnitski, SR-Tiget, Milan / University of Pavia INV50: Dissecting Cell Intrinsic Innate Immunity against Viral Vectors	
Sophie Janssens, University of Ghent and VUB, Belgium INV51: Lipid nanoparticles induce homeostatic dendritic cell maturation and do not contain intrinsic adjuvant activity.	
Fraser Wright, Stanford University OR079: Engineering albumin-binding domains into the capsid protein of AAV: A transient cloaking mechanism to block antibody binding for imp vector safety and efficacy	proved
Andrea Annoni, SR-Tiget, Milan OR080: Co-stimulatory blockade regimen prevents anti-transgene and anti-vector immune responses in hemophilia A mice after <i>in vivo</i> LV gene therapy.	ə
Allwyn Pereira, University of Nantes OR081: Assessing molecular mechanisms of microglial mediated inflammation in retinal gene therapy	
Svetlana Atasheva, Emory University OR082: Immunological Safety of Adenoviral Vector Gene Therapy.	

_	THURSDAY 24 OCTOBER
	:30-17:30 · Meeting Room 2 · PARALLEL ESSION 9c: Immunotherapy and CAR-T Cells II CellforCURE
Ch	nairs: Monica Casucci, IRCCS San Raffaele Scientific Institute, Milan; Carmen Sanges, University of Würzburg
	hiara Magnani, University Hospital Zürich and University of Zürich IV52: Activity, biological properties, and safety of non-viral CAR T cells engineered with Sleeping Beauty for hematological malignancies
	ara Ghorashian, University College London IV53: Overcoming current limitations in CAR T cell therapy of ALL
	rianna Pocaterra, IRCCS San Raffaele Scientific Institute, Milan R083: T cell therapy for PDAC: overcoming resistance by tumor/stroma dual-targeting CAR-T cells
	upert Kenefeck, Quell Therapeutics R084: CAR-Treg cell therapy to induce tolerance in liver transplantation – LIBERATE clinical trial
O	ariana Silva, Vor Bio, Cambridge R085: Novel CD33/CLL-1-directed dual CAR-T cells mediate potent antigen-specific cytolytic activity in mouse models of Acute Myeloid Leukemia ML)
	aula Rodriguez-Marquez, Cima Universidad de Navarra. IdiSNA. Pamplona R086: Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma
S	:30-17:30 · Auditorium · PARALLEL ESSION 9d: Accessibility of Gene Therapy nairs: Hildegard Büning, Hannover Medical School, Stefano Benvenuti, Fondazione Telethon
	nit Nathwani, LifeArc IV54: Improving access for rare disease drugs
	bl Ruiz, AEMPS IV55: Regulatory progress
	erry Pirovolakis, CureSPG50 IV56: Journey to cure
	avid Epstein, University of Granada IV57: The economics of gene therapies
	rjan Lankester, <i>LUMC, Leiden</i> IV59: Access to gene therapy, the AGORA perspective
	nnette Künkele-Langer, <i>Join4ATMP</i> IV60: Map, join and drive European activities for ATMP development and implementation - JOIN4ATMP
Pa	anel Discussion
	:30-18:00 · Forum and Registration Foyer OFFEE BREAK
SI fo	:30-19:30 · Auditorium · PARALLEL ESSION 10: Towards the Accessibility of ATMPs for Rare and Ultra-rare Diseases with No Commercial Interest: Is there a role or Hospital Exemption?
AI	nairs: Juan Bueren, CIEMAT/CIBERER/IIS. F. Jiménez Díaz, Madrid; Alessandro Aiuti, SR-Tiget, Milan; Claire Booth, University College London Ressandro Aiuti, SR-Tiget, Milan IV61: Challenges in ATMPs development and access to patients for rare and ultra-rare diseases
	aschalia Koufokotsiou, European commission IV62: Current meaning and legislation of Hospital Exemption in the EU
	bl Ruiz, <i>AEMPS, Madrid</i> IV63: Key standards for the harmonization of HE across the EU
El Cr	anel Discussion: isabetta Zanon: Director of EU Public Affairs & Advocacy. Alliance for Regenerative Medicine ristina Avendaño-Sola: Spanish Network on Advanced Therapies (TERAV) ohan Prevot: International Patient Organization for Primaries Immunodeficiencies; IPOPI
	:00-19:30 · Concourse Level -1 and Mezzanine Concourse OSTER SESSION IV (Even numbers from P0522 to P1046)

FRIDAY 25 OCTOBER
08:30-09:00 · Registration Foyer REGISTRATION
09:00-10:30 · Plenary Hall · PARALLEL SESSION 11a: Immunotherapy and CAR T cells III In collaboration with ASGCT
Chairs: Paula Cannon, University of Southern California; Chiara Bonini, San Raffaele Hospital, Milan
Paula Cannon, University of Southern California INV64: Engineering B cells for custom antibody production
David Klatzmann, UPMC, Sorbonne University INV65: Self-sufficiency for an IL-2 partial agonist dramatically improves survival and efficacy of Treg cell therapy
Nils Wellhausen, University of Pennsylvania OR087: Elimination of cellular HIV reservoirs by CCR5/CD45 multiplex base edited CD45 CAR-T cell therapy
Martina Pigazzi, University-Hospital of Padova, Padua OR088: Successful Preclinical Proof-of-Concept Study of a CAR-T Cell Approach Targeting CD84 to Treat Acute Myeloid Leukemia
09:00-10:30 · Meeting Room 1 · PARALLEL SESSION 11b: Beyond conventional: next generation vectors in gene and cell therapy, part II (AAV genome, genome editing)
Chairs: Leszek Lisowski, Children Medical Research Institute, Sydney; Giuseppe Ronzitti, Genethon, Evry
Arun Srivastava, University of Florida INV68: Beyond capsid-modifications: Development of genome-modified AAV vectors
Sibtain Haider, Universitäts klinikum Freiburg OR089: Peptide-assisted tethering of DNA repair effectors to Cas9 for precise genome editing
Caner Günaydin, Weill Cornell Medical College OR090: Genome Editing of Human APOE4 to APOE3 in the Brain of APOE4 Mice
Federica Fioretto, <i>Tigem, Naples</i> OR091: Mutation-independent genome editing approaches for treatment of Stargardt disease
Phillip Tai, UMass Chan Medical School OR092: Novel inverted terminal repeat sequences and flanking proximal regions from serotypes AAV8 and AAV.rh39 show robust promoter-like activities that enhance transgene expression in a tissue-dependent manner
09:00-10:30 · Meeting Room 2 · PARALLEL
PARALLEL 11c: Disease Models / IPS cells / Organoids Cell Therapy Chairs: Markus Grompe, Oregon Health & Science University, Portland; Vania Broccoli, San Raffaele Scientific Institute, Milan / CNR Institute of Neuroscience, Milan
Benedetta Artegiani, Princess Máxima Center for Pediatric Oncology, Utrecht INV69: Human organoid models for disease modeling
Vania Broccoli, San Raffaele Scientific Institute, Milan / CNR Institute of Neuroscience, Milan INV70: Generation of fully human pluripotent stem cell-derived blood-brain barrier organoids for disease modeling and validation of neurotropic viruses
Maria del Carmen Ortuño Costela, Berlin Institute of Health OR093: Generation of hepatocyte organoids from primary hepatocytes
Martina Nubiè, Institute for Regenerative Medicine (IREM), University of Zurich OR094: Investigating the effects of progranulin reconstitution driven by microglia-directed gene therapy in iPSC-derived neural networks
09:00-10:30 · Auditorium · PARALLEL SESSION 11d: New Tools and Delivery for Gene Editing Chairs: Angelo Lombardo, SR-Tiget, Milan; Silvia Roman, University of Freiburg
Toni Cathomen, University of Freiburg INV71: Revelations in Precision: Learning from On- & Off-Target Effects of Gene Editing Tools
Jin Soo Kim, National University of Singapore INV72: Mitochondrial DNA editing in vitro and in vivo
Laura Torella, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona OR095: Investigating the interplay between DNA repair pathways and recombinant AAV integration into CRISPR-Cas-induced double-strand breaks in vivo
Piergiuseppe Quarato, <i>SR-Tiget, Milan</i> OR096: Development of an epigenome editing strategy for the treatment of β -hemoglobinopathies

FRIDAY 25 OCTOBER	
10:30-11:00 · Forum and Registration Foyer COFFEE BREAK	
11:00-13:00 · Plenary Hall · PARALLEL SESSION 12a: Manufacturing <i>Chairs: Cesar Trigueros, Viralgen, San Sebastian; Mercedes Segura, Elevate Bio</i>	
Nina Kotsopoulou, AAVantgard bio INV73: Production of dual AAV vectors for the delivery of large genes	
Margherita Neri, AGC Biologics Milano INV74: Fast lane to market: Designing vector processing and analytical validation, characterization stud	dies for EU/FDA approval
Eduard Ayuso, DINAMIQS INV75: Manufacturing AAV vectors: every step matters	
Simona Porcellini, SR-Tiget, Milan OR097: Gene correction of HIGM1 CD4+ T cells: a comprehensive analysis of GMP-compliant process	s performance and product critical quality attributes
Kumar Dhanasekharan, Voyager Therapeutics OR098: Scaling up manufacturing to 1000L and beyond with novel AAV capsids and payloads: From ea development and scale-up.	arly developability assessment to process
11:00-13:00 · Meeting Room 1 · PARALLEL SESSION 12b: Metabolic Diseases: Clinical Chairs: Maria Ester Bernardo, SR-Tiget, Milan, Alessia Cavazza, University College London	
Julien Baruteau, University College London INV76: mRNA therapy for liver inherited metabolic diseases	
Valentina Poletti, University of Padova INV77: Hematopoietic Stem Cell Gene Therapy for GM1 Gangliosidosis	
Valeria Calbi, SR-Tiget, Milan OR099: Atidarsagene autotemcel (lentiviral hematopoietic stem cell gene therapy) for late juvenile meta a phase III clinical trial	achromatic leukodystrophy: preliminary results from
Sarah Neuhaus, Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company OR100: Phase 1/2 dose-finding study to evaluate systemic administration of an AAV9-based gene there disease: The Proceed Trial	rapy for peripheral manifestations of Gaucher
Emily de los Reyes, Nationwide Children's Hospital OR101: Gene therapy for CLN3, Juvenile neuronal ceroid lipofuscinosis, a promising therapy	
Maria Escolar, Forge Therapeutics OR102: REKLAIM, a Phase I/II clinical trial using a novel immune modulation strategy for systemic adm Umbilical Cord Blood Transplantation for the treatment of Infantile Krabbe Disease	ninistration of FBX-101 (AAVrh10.GALC) after
11:00-13:00 · Meeting Room 2 · PARALLEL SESSION 12c: Non-Viral Vectors / Nanotechnology II Chairs: Marc Güell, Pompeu Fabra University, Barcelona; Gabor Tamas Szabo, BioNTech SE, Mainz	
Raymond Schiffelers, Utrecht University INV78: Towards production of nucleic acid nanomedicines at the bedside	
Hadi Valadi, University of Gothenburg INV79: Utilizing extracellular vesicles for RNA transport and therapeutic applications	
Lucia De Stefano, <i>Tigem, Naples</i> OR103: mRNA-replacement therapy for Glycogen Storage Disease type 1b	
Gilles Divita, DivinCell OR104: A safe Peptide-based, lipid-free, nanoparticle platform for mRNA delivery and gene editing in the hemophilia A and selective editing of PCSK9 gene to durably lowers cholesterol in mice.	the liver: application to Factor VIII rescue in
Vanessa Hamann, Hannover Medical School OR105: Alpharetrovirus-like particles for in vitro and vivo delivery of diagnostic and therapeutic RNAs	
Peter Cabeceiras, Nvelop Therapeutics, Cambridge, MA OR106: DLVR-M: a novel fully humanized particle for the efficient in vivo delivery of large gene-editing of	cargos to human cells

FRIDAY 25 OCTOBER
11:00-13:00 · Auditorium · PARALLEL SESSION 12d: Regulatory Chairs: Ilona Reischl, EMA
Patrick Celis, EMA INV80: 15-years of CAT : what have we achieved, how have ATMP developers benefitted and what is CAT doing now to support ATMP development
Ilona Reischl, Kieran Breen, Emmely de Vries, EMA INV81: CAT Guideline for investigational ATMPs in clinical trials: insights from the Regulator on quality, non-clinical and clinical requirements
Patrick Celis, EMA INV82: EMA/CAT reflection on decentralised manufacturing for ATMPs
Panel discussion
13:00-13:30 · Meeting Room 1 SITGEC AGM
13:00-14:30 · Forum and Registration Foyer LUNCH
13:30-14:15 · Satellite Room - M1 LUNCHTIME WORKSHOP: Am I an effective scientific communicator? EuroGCT and the ECR Board Members will facilitate this workshop on effective communication, highlighting the strongest elements and offering tips for delivering impactful speeches.
Attendees must sign up in advance. Register at https://forms.office.com/e/YnrRv0EM3Y
14:30-16:45 · Plenary Hall · PLENARY SESSION 13: Modeling Human Diseases to Advance Gene and Cell Therapies Chairs: Juan Bueren, CIEMAT/CIBERER/IIS. F. Jiménez Díaz, Madrid; Luigi Naldini, SR-Tiget, Milan; Alberto Auricchio, Tigem, Naples
Manju Kurian, University College London INV83: Modelling neurological disorders to advance gene therapies
Peter Campbell, Wellcome Sanger Institute, Hinxton INV84: Somatic mutations in stem cell transplantation
Claire Henchcliffe, University of California, Irvine INV85: Early clinical trials in developing a stem cell-based therapy in Parkinson's disease
Markus Grompe, Oregon Health & Science University, Portland INV86: In vivo selection to enhance cell and gene therapy
Concluding Remarks
16:45.17:30 .

16:45-17:30 · Farewell drinks - See you in Sevilla